A few months after the new cholesterol guidelines were announced last year, I  went to a free educational luncheon semi-  nar for physicians. It was sponsored by an unrestricted third-party grant from a pharmaceutical company; academic cardiologists from excellent universities made fair-balanced presentations on the subject of cholesterol-lowering drugs.